The pandeacetylase inhibitor panobinostat modulates the expression of epithelialmesenchymal transition markers in hepatocellular carcinoma models

By                

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 127-134

Spandidos Publications

Access to resources Recommend Favorite

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

By Prince H Miles   Bishton Mark J   Johnstone Ricky W  

Future Oncology, Vol. 5, Iss. 5, 2009-06 ,pp. : 601-612

Future Medicine

Access to resources Recommend Favorite

The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype

By            

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 700-708

Spandidos Publications

Access to resources Recommend Favorite

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

By Hainsworth John D.   Infante Jeffrey R.   Spigel David R.   Arrowsmith Edward R.   Boccia Ralph V.   Burris Howard A.  

Cancer Investigation, Vol. 29, Iss. 7, 2011-07 ,pp. : 451-455

Informa Healthcare

Access to resources Recommend Favorite

Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives

By Sun Hui-Chuan   Tang Zhao-You  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 6, 2004-06 ,pp. : 307-319

Springer Publishing Company

Access to resources Recommend Favorite